NYC Bioscience Newsletter connects you to the latest information on Bio & Health Tech NYC.
NYCEDC April 22, 2015
NYC Bioscience Newsletter

Launch of NYC Early-Stage Life Sciences Funding Initiative ›

On March 30th, NYCEDC and the City of New York launched the Early-Stage Life Sciences Funding Initiative, a historic $150M co-investment partnership to build new life sciences ventures in New York City. With the support of industry partners Celgene Corporation, GE Ventures, and Eli Lilly and Company (Lilly), NYCEDC announced the Initiative’s two top-tier venture capital partners, Flagship Ventures and ARCH Venture Partners. These firms will manage separate investment activities within the Funding Initiative and will each establish a presence in New York City. 

In The News


Cellectis Opens Labs in NYC ›
Cellectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells. The company’s mission is to develop a new generation of cancer therapies. “We were convinced by the outstanding potential of New York City, one of the fastest expanding biotech hubs in the world,” said Dr. André Choulika, Founder, Chief Executive Officer and Chairman of Cellectis.

Oscar Raises $145M, Valued at $1.5B ›
Oscar, a New York City-based company working to transform the health insurance industry, raised a round from investor, Peter Thiel's Founders Fund, as well as other investors including Horizon Ventures, the Wellington Management Company, and Goldman Sachs. Oscar's latest valuation, at $1.5 billion, is more than three times its valuation at the start of 2014.

Ovid Therapeutics Raises Over $5M ›
New York City-based Ovid Therapeutics targets rare neurological diseases, including Angelman Syndrome and Fragile X Syndrome. The company recently raised $5M and announced the former head of Teva Pharmaceuticals, Jeremy Levin, as CEO. 

Provista Diagnostics Raises Almost $4M ›
New York City-headquartered Provista Diagnostics is focused on developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic, and monitoring tests designed to address the unmet needs in women’s cancer, such as breast and gynecologic cancers. The company recently raised $3.87M.

HistoWiz Raises $1M ›
New York City-based HistoWiz, Inc., a participant in NYCEDC’s ELABNYC and SBIR Impact NYC programs, is a histopathology service company for cancer researchers in academia and pharma. The company's mission is to fight cancer cooperatively by connecting scientists and doctors for online collaboration. The company recently raised $1M through angel investors.

NomoCan Pharmaceuticals Raises $740K ›
New York City-based NomoCan Pharmaceuticals a participant in NYCEDC’s ELABNYC, offers the first-in-­kind targeted therapy for the treatment of pancreatic cancer. The company recently raised $740K from angel investors. The company is operating out of the SUNY Downstate Bio-incubator, a NYS designated tax-­free STARTUP NY zone in Brooklyn.  

NYCEDC SBIR Training Events in May ›
SBIR IMPACT NYC - Application Cycle Deadline, April 22
Each year, SBIR Impact NYC offers select companies specialized SBIR/STTR application assistance. To apply for the current cycle, please submit your application by April 22.

Riverside Chats
SBIR Award Winner Panel, May 19 - Register Now

Intro to SBIR/STTR and NIH Proposal Preparation, May 21
The Session will be conducted by nationally recognized SBIR/STTR expert, Lisa Kurek, Director of the SBIR Imapct NYC Program - Register Now

AllazoHealth Announces a Research Partnership ›
New York City based AllazoHealth, a Pilot Health Tech NYC winner, announced a research partnership with Pharmacy Quality Alliance to study and improve the medication adherence metrics used industry-wide. AllazoHealth is a predictive analytics firm that is tackling the problem of medication non-adherence. 

Pager Raises Over $10M ›
New York City-based Pager provides on-demand doctor visits via mobile devices. The company recently raised $10.4M in its first funding round.

Lauren Sciences Awarded Campbell Foundation Grant ›
New York City-based Lauren Sciences develops therapeutics for patients with severe unmet medical needs, especially CNS diseases such as Parkinson’s, AIDS, ALS, GBM, Alzheimer’s, LSDs and others. The company was recently awarded a grant by the Campbell Foundation to continue development of a V-SmartTM therapeutic for Neuro-HIV.

Upcoming Events

April 22
Health Sciences Innovation Investment Forum - American Heart Association
Alexandria Center
April 22
SBIR IMPACT NYC - Application Cycle Deadline, April 22
Online
 
April 24
Bourbon and Beakers - Monthly Harlem Biospace Happy Hour
Harlem Biospace
April 27
Trends & Strategies in Financing Early-Stage Life Science Startups
Harlem Biospace
May 4 - 5 
NewYorkBIO 25th Anniversary Conference
10 on the Park @ Time Warner Center
May 19
Riverside Chats - SBIR Award Winner Panel
NY Blood Center
May 21
Intro to SBIR/STTR and NIH Proposal Preparation
NY Genome Center
June 2
1st Pitch Life Sciences
NY Genome Center
 
June 15 - 18
2015 BIO International Convention
Pennsylvania Convention Center

Leasing Opportunities

Who's Hiring in NYC Bioscience

Learn about additional opportunities on Harlem Biospace's Job Board.

You May Also Like...

Biotech Incubator in Manhattan

Harlem Biospace (Hb), a new biotech incubator and the first of its kind in NYC to offer affordable, shared, wet-lab space for competitively-selected entrants, opened in November 2013. Learn more at harlembiospace.com.

NYC: A Leader in Life Sciences

Building upon its world-class research institutions, New York City's commercial life science industry has recently gained momentum.

             


Subscribe to the NYC Bioscience Newsletter
Edit your subscription
Unsubscribe lharcum@nycedc.com from this list

Mailing Address
NYCEDC
110 William Street
New York, NY 10038

Add us to your address book